| Public | NASDAQ:RXII |
| Website | rxipharma.com |
| Category | BioTech |
| Phone | 508-767-3861 |
| admin@RXiPharma.com | |
| Employees |
| Apthera, 3/11 | $7M |
| TOTAL | $300k |
| FUNDING TOTAL | $300k |
| Grant, 10/12 National Cancer Institute | $300k |
RXi Pharmaceuticals Corporation is a discovery-stage biopharmaceutical company pursuing therapeutics based on ribonucleic acid (RNA) interference (RNAi). RNAi therapeutic platform includes two components: Novel RNAi Compounds and Advanced Delivery Technologies. The Company has developed a number of forms of rxRNA compounds. These RNAi compounds include rxRNAori, rxRNAsolo and sd-rxRNA, or self delivering RNA. The suite of delivery technologies is comprised of delivery vehicles, which could be combined with various rxRNA compounds, as well as sd-rxRNA compounds, which are chemically modified and have the property of entering cells and tissues to effect silencing without the need for any additional delivery vehicle.
